The Priority Review

The stream · Daily digest

The stream: Monday, November 2, 2026

11 briefs from ClinicalTrials.gov and FDA, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 5

  1. Specific Biologics announces oversubscribed US$35 million Series A financing

    Specific Biologics announced the closing of an oversubscribed US$35 million Series A financing led by Hatteras Venture Partners, with participation from Lumira Ventures, adMare BioInnovations and other investors. The proceeds will be used to advance the lead Dualase therapeutic candidate through initial clinical biomarker proof-of-concept in the first cohort of an adaptive Phase I/II clinical trial in patients with C9ORF72-associated ALS.

    Source: Company press release (PR Newswire), November 2, 2026

  2. Keymed registers Phase 3 trial of CM336+CM313 in relapsed multiple myeloma

    The study, led by Keymed Biosciences Co.Ltd, plans to enroll 320 participants and start in December 2026. It compares CM336+CM313 with Daratumumab+Pomalidomide+Dexamethasone in patients who have received 1 to 3 prior lines of therapy.

    Source: ClinicalTrials.gov registry record, November 2, 2026

  3. Merck registers Phase 3 trial of Gocatamig with Durvalumab in small cell lung cancer

    Merck Sharp & Dohme LLC has registered a Phase 3 randomized study to evaluate the safety and efficacy of Gocatamig (MK-6070) with Durvalumab versus Durvalumab alone as consolidation therapy in limited-stage small cell lung cancer. The trial plans to enroll 564 participants and is expected to start on December 7, 2026.

    Source: ClinicalTrials.gov registry record, November 2, 2026

  4. Guangzhou Patronus registers Phase III trial of LYB005 RSV vaccine in older adults

    The Guangzhou Patronus Biotech Co., Ltd. study plans to enroll an estimate of 25000 participants aged 60 years and older, with a planned start date of November 2026 and a planned primary completion date of September 2027. The trial is randomized, observer-blind, and placebo-controlled.

    Source: ClinicalTrials.gov registry record, November 2, 2026

  5. Novo Nordisk posts results of Phase 3 semaglutide trial in HFpEF with diabetes

    The company posted results of a completed Phase 3 study that enrolled 617 participants with heart failure with preserved ejection fraction and type 2 diabetes, comparing semaglutide 2.4 mg once-weekly to a dummy medicine. The trial began on June 15 2021 and reached primary completion on October 11 2023.

    Source: ClinicalTrials.gov results record, November 2, 2026

Policy · 4

  1. BioMarin reports third quarter 2026 financial and operating results

    BioMarin said total revenues for the third quarter ended September 30, 2026 rose 32% year-over-year to $1.025 billion, driven by 44% growth in metabolic conditions and 12% growth in skeletal conditions. The company also announced a PDUFA target action date of May 30, 2027 for VOXZOGO in hypochondroplasia and that the EMA validated its submission for VOXZOGO in HCH.

    Source: Company press release (PR Newswire), November 2, 2026

  2. BioArctic says Novartis terminates collaboration agreement

    BioArctic AB announced that Novartis Pharma AG has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025. The company will retain the full USD 30 million upfront payment and recognize the remaining unrecognized portion as revenue in 2026.

    Source: Company press release (PR Newswire), November 2, 2026

  3. Brise Pharmaceuticals announces license agreement with AbbVie to advance migraine therapies

    Brise said the agreement, entered in 2024, gives AbbVie global development and commercialization rights for two of Brise's preclinical migraine programs. The aggregated potential transaction value could reach up to US $757 million plus royalties on future sales.

    Source: Company press release (PR Newswire), November 2, 2026

  4. Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline

    Fresenius SE & Co. KGaA announced an exclusive development agreement with WuXi Biologics that gives Fresenius access to up to 37 identified biosimilar candidates over the next decade, potentially expanding its portfolio from 29 to up to 66 molecules. The agreement, the largest in the biosimilars industry to date, preserves Fresenius' full commercialization economics and strategic flexibility.

    Source: Company press release (PR Newswire), November 2, 2026

Regulation · 2

  1. Roche receives FDA 510(k) clearance for new cobas eplex respiratory pathogen panel 3

    Roche announced the FDA 510(k) clearance of the cobas eplex respiratory pathogen panel 3 (RP3), a flexible syndromic test that detects up to 19 viral and bacterial targets from a single nasopharyngeal swab. The panel offers up to five customizable configurations, requires less than one minute of hands-on time, and delivers results in under two hours.

    Source: Company press release (PR Newswire), November 2, 2026

  2. FDA issues final guidance for cell and gene therapy manufacturers

    The FDA today issued final guidance for cellular and gene therapy (CGT) manufacturers, replacing its 2011 potency testing guidance and recommending a Potency Assurance Strategy for products treating serious or life-threatening conditions. The FDA will host a webinar on December 10, 2026 to help stakeholders understand and implement the guidance.

    Source: FDA press announcement, November 2, 2026